Literature DB >> 28994285

Biologically Inspired Design of Nanoparticle Artificial Antigen-Presenting Cells for Immunomodulation.

John W Hickey1, Fernando P Vicente1, Gregory P Howard1, Hai-Quan Mao1, Jonathan P Schneck1.   

Abstract

Particles engineered to engage and interact with cell surface ligands and to modulate cells can be harnessed to explore basic biological questions as well as to devise cellular therapies. Biology has inspired the design of these particles, such as artificial antigen-presenting cells (aAPCs) for use in immunotherapy. While much has been learned about mimicking antigen presenting cell biology, as we decrease the size of aAPCs to the nanometer scale, we need to extend biomimetic design to include considerations of T cell biology-including T-cell receptor (TCR) organization. Here we describe the first quantitative analysis of particle size effect on aAPCs with both Signals 1 and 2 based on T cell biology. We show that aAPCs, larger than 300 nm, activate T cells more efficiently than smaller aAPCs, 50 nm. The 50 nm aAPCs require saturating doses or require artificial magnetic clustering to activate T cells. Increasing ligand density alone on the 50 nm aAPCs did not increase their ability to stimulate CD8+ T cells, confirming the size-dependent phenomenon. These data support the need for multireceptor ligation and activation of T-cell receptor (TCR) nanoclusters of similar sizes to 300 nm aAPCs. Quantitative analysis and modeling of a nanoparticle system provides insight into engineering constraints of aAPCs for T cell immunotherapy applications and offers a case study for other cell-modulating particles.

Entities:  

Keywords:  Artificial antigen presenting cell; CD8+ T cell; immunotherapy; nanoparticle; particle size; receptor clustering

Mesh:

Substances:

Year:  2017        PMID: 28994285      PMCID: PMC6709596          DOI: 10.1021/acs.nanolett.7b03734

Source DB:  PubMed          Journal:  Nano Lett        ISSN: 1530-6984            Impact factor:   11.189


  64 in total

1.  Determination of the relationship between T cell responsiveness and the number of MHC-peptide complexes using specific monoclonal antibodies.

Authors:  P A Reay; K Matsui; K Haase; C Wulfing; Y H Chien; M M Davis
Journal:  J Immunol       Date:  2000-06-01       Impact factor: 5.422

2.  Ex vivo induction and expansion of antigen-specific cytotoxic T cells by HLA-Ig-coated artificial antigen-presenting cells.

Authors:  Mathias Oelke; Marcela V Maus; Dominic Didiano; Carl H June; Andreas Mackensen; Jonathan P Schneck
Journal:  Nat Med       Date:  2003-04-21       Impact factor: 53.440

3.  T cell killing does not require the formation of a stable mature immunological synapse.

Authors:  Marco A Purbhoo; Darrell J Irvine; Johannes B Huppa; Mark M Davis
Journal:  Nat Immunol       Date:  2004-03-28       Impact factor: 25.606

4.  Clustering class I MHC modulates sensitivity of T cell recognition.

Authors:  David R Fooksman; Gigi Kwik Grönvall; Qing Tang; Michael Edidin
Journal:  J Immunol       Date:  2006-06-01       Impact factor: 5.422

5.  Adoptive transfer of cloned melanoma-reactive T lymphocytes for the treatment of patients with metastatic melanoma.

Authors:  M E Dudley; J Wunderlich; M I Nishimura; D Yu; J C Yang; S L Topalian; D J Schwartzentruber; P Hwu; F M Marincola; R Sherry; S F Leitman; S A Rosenberg
Journal:  J Immunother       Date:  2001 Jul-Aug       Impact factor: 4.456

6.  Ribosomal protein S6 phosphorylation is a determinant of cell size and glucose homeostasis.

Authors:  Igor Ruvinsky; Nitzan Sharon; Tal Lerer; Hannah Cohen; Miri Stolovich-Rain; Tomer Nir; Yuval Dor; Philip Zisman; Oded Meyuhas
Journal:  Genes Dev       Date:  2005-09-15       Impact factor: 11.361

7.  T cell receptor signaling precedes immunological synapse formation.

Authors:  Kyeong-Hee Lee; Amy D Holdorf; Michael L Dustin; Andrew C Chan; Paul M Allen; Andrey S Shaw
Journal:  Science       Date:  2002-02-22       Impact factor: 47.728

8.  Phase I study of adoptive T-cell therapy using antigen-specific CD8+ T cells for the treatment of patients with metastatic melanoma.

Authors:  Andreas Mackensen; Norbert Meidenbauer; Sandra Vogl; Monika Laumer; Jana Berger; Reinhard Andreesen
Journal:  J Clin Oncol       Date:  2006-11-01       Impact factor: 44.544

9.  Dendritic cells are dysfunctional in patients with operable breast cancer.

Authors:  Sukchai Satthaporn; Adrian Robins; Wichai Vassanasiri; Mohamed El-Sheemy; Jibril A Jibril; David Clark; David Valerio; Oleg Eremin
Journal:  Cancer Immunol Immunother       Date:  2004-01-23       Impact factor: 6.968

10.  Altered maturation of peripheral blood dendritic cells in patients with breast cancer.

Authors:  S Della Bella; M Gennaro; M Vaccari; C Ferraris; S Nicola; A Riva; M Clerici; M Greco; M L Villa
Journal:  Br J Cancer       Date:  2003-10-20       Impact factor: 7.640

View more
  35 in total

1.  Enrich and Expand Rare Antigen-specific T Cells with Magnetic Nanoparticles.

Authors:  John W Hickey; Jonathan P Schneck
Journal:  J Vis Exp       Date:  2018-11-17       Impact factor: 1.355

Review 2.  Nanovaccines for cancer immunotherapy.

Authors:  Yu Zhang; Shuibin Lin; Xiang-Yang Wang; Guizhi Zhu
Journal:  Wiley Interdiscip Rev Nanomed Nanobiotechnol       Date:  2019-06-06

Review 3.  Applications of molecular engineering in T-cell-based immunotherapies.

Authors:  David A McBride; Matthew D Kerr; Shinya L Wai; Nisarg J Shah
Journal:  Wiley Interdiscip Rev Nanomed Nanobiotechnol       Date:  2019-04-10

Review 4.  Biomimetic Nanotechnology toward Personalized Vaccines.

Authors:  Jiarong Zhou; Ashley V Kroll; Maya Holay; Ronnie H Fang; Liangfang Zhang
Journal:  Adv Mater       Date:  2019-06-17       Impact factor: 30.849

Review 5.  Bioconjugate Strategies for the Induction of Antigen-Specific Tolerance in Autoimmune Diseases.

Authors:  Chunsong Yu; Jingchao Xi; Meng Li; Myunggi An; Haipeng Liu
Journal:  Bioconjug Chem       Date:  2017-12-06       Impact factor: 4.774

Review 6.  Nanomedicine and macroscale materials in immuno-oncology.

Authors:  Qingxue Sun; Matthias Barz; Bruno G De Geest; Mustafa Diken; Wim E Hennink; Fabian Kiessling; Twan Lammers; Yang Shi
Journal:  Chem Soc Rev       Date:  2019-01-02       Impact factor: 54.564

Review 7.  Nanomedicine and Onco-Immunotherapy: From the Bench to Bedside to Biomarkers.

Authors:  Vanessa Acebes-Fernández; Alicia Landeria-Viñuela; Pablo Juanes-Velasco; Angela-Patricia Hernández; Andrea Otazo-Perez; Raúl Manzano-Román; Rafael Gongora; Manuel Fuentes
Journal:  Nanomaterials (Basel)       Date:  2020-06-29       Impact factor: 5.076

Review 8.  T cell immunotherapy enhanced by designer biomaterials.

Authors:  Zachary S Dunn; John Mac; Pin Wang
Journal:  Biomaterials       Date:  2019-06-14       Impact factor: 12.479

9.  Engineering an Artificial T-Cell Stimulating Matrix for Immunotherapy.

Authors:  John W Hickey; Yi Dong; Jae Wook Chung; Sebastian F Salathe; Hawley C Pruitt; Xiaowei Li; Calvin Chang; Andrew K Fraser; Catherine A Bessell; Andrew J Ewald; Sharon Gerecht; Hai-Quan Mao; Jonathan P Schneck
Journal:  Adv Mater       Date:  2019-04-10       Impact factor: 30.849

Review 10.  Improving cancer immunotherapy through nanotechnology.

Authors:  Michael S Goldberg
Journal:  Nat Rev Cancer       Date:  2019-09-06       Impact factor: 60.716

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.